Business EconomyPosted at: Mar 20 2025 6:42PM


Bharat Biotech forays into Cell & Gene Therapy

Hyderabad, Mar 20 (UNI) Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, on Thursday announced its foray into Cell & Gene Therapy (CGT).
In a release, the Hyderabad based vaccine maker also informed that it's Viral Vector Production at Genome Valley - expanding its expertise from vaccine innovation to leading-edge regenerative and personalised therapies that promise hope for millions.
This ushers in a new era of gene and cell therapies to tackle scientific challenges—such as targeted gene expression, immune system modulation, and long-term cell survival— The work will span from boosting immune responses against cancer to ensuring that therapeutic proteins are safely accepted in patients with genetic diseases like hemophilia.
The 50,000-square-foot dedicated state-of-the-art CGT facility represents the next milestone in BBIL’s long-standing mission to deliver targeted, life-saving treatments that address unmet clinical needs globally by concentrating on critical conditions such as hematological malignancies and inherited blood disorders.
Outlining the purpose behind establishing India’s only vertically integrated cell and gene therapy facility, Dr. Krishna Ella, Executive Chairman, Bharat Biotech said, “Gene and cell therapies represent some of the most intricate, scientifically advanced treatments available today, involving sophisticated processes that require expertise in precise genetic manipulation and specialized manufacturing capabilities.
Bharat Biotech, with its extensive experience and proven excellence in viral vaccine manufacturing is uniquely positioned to master these complexities and produce human-grade vectors at the scale and consistency needed for clinical trials, thus advancing the global fight against rare and complex diseases.”
Dr. Raches Ella, Chief Development Officer, Bharat Biotech, spearheading this CGT initiative, said “Bharat aims to democratize gene therapies, traditionally considered prohibitively expensive and available primarily in developed nations or premium institutions. Our established expertise in producing viral vectors are essential for cell and gene therapy applications - the crucial material for anti-cancer and genetic disorders and robust clinical development abilities for QC release".
Additionally, it has capabilities to manufacture multiple platform products for various disease indications, including blood cancers, solid organ cancers, and genetic disorders, Dr. Raches added.
Prof. Krishanu Saha, University of Wisconsin, Madison, said,“My lab has initiated a pioneering collaboration with Bharat Biotech to develop next-generation CAR (chimeric antigen receptor) cell therapies using AI. Ultimately, genuine innovations in both product design and scaling will enhance patient care globally.”

“Cell & Gene Therapy aligns with BBIL’s broader vision of expanding beyond traditional vaccines into personalized medicine. Leveraging our proven expertise in forging strategic global partnerships, this initiative will enable the rapid translation of advanced scientific discoveries—from potent therapeutic vectors to in vivo CAR (chimeric antigen receptor) generation—into real-world solutions.” Dr. Krishna Ella added.
UNI KNR CS
Please log in to get detailed story.
Tags: #Bharat Biotech forays into Cell & Gene Therapy
More News

Market valuation of 8 of top10 firms surges by over Rs 1 87 lakh cr

19 Apr 2026 | 5:43 PM

New Delhi, April 19 (UNI) The combined market valuation of eight of the top-10 most valued firms surged by Rs 1,87,497.45 crore last week. Bharti Airtel emerged as the biggest gainer, as its market valuation jumped Rs 58,831.52 crore to Rs 11,25,125.21 crore.

see more..

Molecules enters Japan to boost research collaboration

19 Apr 2026 | 5:19 PM

Mumbai, Apr 19 (UNI) Molecules has expanded its global footprint by establishing a facility in Tokyo to accelerate collaborative research programmes involving academia, industry and technology partners across Japan, India and other key innovation hubs, the company said.

see more..

Over 73,200 IT layoffs recorded in first 3 months of 2026

19 Apr 2026 | 3:57 PM

New Delhi, Apr 19 (UNI) Over 73,200 jobs were cut in the initial three months of 2026 Q1FY26 by 95 Information Technology (IT) companies, data compiled by Layoffs. fyi said.

see more..

Cabinet okays additional instalment of DA to central govt employees and DR to pensioners

18 Apr 2026 | 4:57 PM

New Delhi, April 18 (UNI) The union Cabinet on Saturday approved an additional installment of Dearness Allowance (DA) for Central government employees and Dearness Relief (DR) for pensioners, offering relief amid rising prices.

see more..

Tea bodies urge PM Modi to scrap mandatory auction norms, seek market freedom

17 Apr 2026 | 7:29 PM

Siliguri, Apr 17 (UNI) Four major tea industry bodies from Assam and North Bengal have jointly appealed to Prime Minister Narendra Modi, seeking urgent amendments to existing regulations mandating the compulsory sale of tea through public auctions, warning that the policy is placing severe financial and operational strain on producers.

see more..